# EDGAR Filing Document

**Accession Number:** 0001837607
**File Stem:** 0001213900-26-009802
**Filing Date:** 2026-1
**Character Count:** 11602
**Document Hash:** e94f8686e3832128c8bc19434031b7d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-009802.hdr.sgml**: 20260129

**ACCESSION NUMBER**: 0001213900-26-009802

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260129

**DATE AS OF CHANGE**: 20260129

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AEON Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001837607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 853940478
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92271
- **FILM NUMBER:** 26580206

**BUSINESS ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** (949) 354-6499

**MAIL ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Priveterra Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201222
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Daewoong Co., Ltd
- **CENTRAL INDEX KEY:** 0001985493

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** M5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 244, GALMACHI-RO, JUNGWON-GU
- **CITY:** SEONGNAM-SI, GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 13211
- **BUSINESS PHONE:** 82-2-550-8800

**MAIL ADDRESS:**
- **STREET 1:** 244, GALMACHI-RO, JUNGWON-GU
- **CITY:** SEONGNAM-SI, GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 13211

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**AEON Biopharma, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**00775E102**

*(CUSIP Number)*

**Daewoong Co., Ltd.**<br>244, Galmachi-ro, Jungwon-gu,<br>Seongnam-si, Gyeonggi-do M5 13211<br>82-02-550-8800

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/21/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00775E102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Daewoong Co.,Ltd. ("DWC")** | Name of reporting person<br>**Daewoong Co.,Ltd. ("DWC")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**58023.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12009737.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**58023.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12009737.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12009737.00** | Aggregate amount beneficially owned by each reporting person<br>**12009737.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**49.99%** | Percent of class represented by amount in Row (11)<br>**49.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** DWC owns 52% of DWP outstanding shares, and therefore has beneficial ownership, voting power and dispositive power over the 23,137,028 shares of Common Stock owned by DWP.

Calculated based on 24,042,282 shares of Common Stock outstanding as of January 21, 2026.

| **CUSIP No.** | **00775E102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Daewoong Pharmaceutical Co. Ltd ("DWP")** | Name of reporting person<br>**Daewoong Pharmaceutical Co. Ltd ("DWP")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**11951714.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**11951714.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12009737.00** | Aggregate amount beneficially owned by each reporting person<br>**12009737.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**49.75%** | Percent of class represented by amount in Row (11)<br>**49.75%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
AEON Biopharma, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
5 Park Plaza, Suite 1750, Irvine, CA, 92614

**Item 4. Purpose of Transaction**

The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference.

DWC is a shareholder of DWP with 52% of shares outstanding.

DWP is the counterparty to the Issuer's license agreements for License & Supply Agreement, effective as of December 20, 2019, as amended, with DWP to provide the Issuer exclusive rights to commercialize and distribute ABP-450 in certain territories.

Our future success currently depends entirely on the successful and timely regulatory approval and commercialization of the Issuer's only product candidate, ABP-450. The Issuer plans to develop ABP-450 to address the estimated $3.0 billion global therapeutic botulinum toxin market, which is projected to grow to $4.4 billion in 2027. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by DWP, in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the FDA, Health Canada and EMA.

The purpose of transaction is part of the Reporting Persons' efforts to strengthen the partnership with the Issuer, whose goal is to achieve development of ABP-450, for which the parties have previously worked together to gain certain approvals from the U.S. Food and Drug Administration (FDA). The Reporting Persons intend to review its investment in the Issuer on an ongoing basis, and currently have no intent to sell, transfer or otherwise dispose of Common Stock reported herein in the foreseeable future.

Subject to applicable legal requirements, the Reporting Persons may purchase additional shares of Common Stock or other securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Person's ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. The Reporting Persons reserve the right to increase or decrease its holdings on such terms and at such times as they may decide.

Except as set forth herein, the Reporting Persons currently have no plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Common Stock and percentage of the shares of Common Stock beneficially owned by the Reporting Persons. The percentage used in this Schedule 13D is calculated based upon 24,024,282 shares of Common Stock issued and outstanding as of January 21, 2026, as reported in the Issuer's Current Report on Form 8-K as filed with the Securities and Exchange Commission (the "SEC") on January 21, 2026.

**(b)**
See rows (7) through (10) of the cover page to this Schedule 13D for the number of shares of Common Stock, as to which the Reporting Persons have the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

**(c)**
There have been no transactions with respect to Shares of the Issuer within the last 60 days by the Reporting Persons, other than the Exchange as described in Item 3 above.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth under Items 3, 4 and 5 of this Schedule 13D is incorporated herein by reference.

Except as disclosed in this Schedule 13D(Including Item 6.), or as set forth in or contemplated in SEC filings submitted by AEON Biopharma or DWC, there are no other contracts, arrangements, understandings or relationships among the persons named in Item 2 with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Daewoong Co.,Ltd. ("DWC")

**Signature:** /s/ Kyu Sung Lim

**Name/Title:** Kyu Sung Lim/Authorized Signatory of Daewoong Co., Ltd.

**Date:** 01/23/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Daewoong Pharmaceutical Co. Ltd ("DWP")

**Signature:** /s/ Woo Hyun Kim

**Name/Title:** Woo Hyun Kim/Authorized Signatory of Daewoong Pharmaceutical Co., Ltd.

**Date:** 01/23/2026